TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35869124

Group type: EXPERIMENTAL
Intervention: Open radical retropubic prostatectomy
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: External radiotherapy
Number of subjects: 704
Study: 35869128

Group type: EXPERIMENTAL
Intervention: EVAL-PLH study (prospective cohort study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data collection at two points (2015-2016 and 2020-2021)
Number of subjects: 0
Study: 35869143

Group type: EXPERIMENTAL
Intervention: First therapy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Subsequent therapies
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 128
Study: 35869170

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (180 mg daily for 28 days in cohort 1; 270-360 mg daily for up to 365 days in cohort 2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 27
Study: 35869429

Group type: EXPERIMENTAL
Intervention: NPi differential (difference ≥ 0.7 between left and right eye) in stroke patients
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: NPi differential (difference ≥ 0.7 between left and right eye) in TBI patients
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: NPi differential (difference ≥ 0.7 between left and right eye) with abnormal NPi (< 3.0)
Number of subjects: 1385
Study: 35869438

Group type: EXPERIMENTAL
Intervention: Joint modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-stage methods (naïve, landmark analysis, time-dependent Cox model, regression calibration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression calibration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-stage methods with sample-based measures
Number of subjects: 0
Study: 35869500

Group type: EXPERIMENTAL
Intervention: BOLT+PTC (brief online training and post-training consultation)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (services as usual)
Number of subjects: 75
Study: 35869557

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 3074

Group type: COMPARATOR
Intervention: Primary invasive mechanical ventilation (IMV)
Number of subjects: 3074
Study: 35869810

Group type: EXPERIMENTAL
Intervention: TIPS insertion with significant PPG reduction
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: TIPS insertion with ascites control
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Higher PPG reduction by TIPS
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Lower PPG after TIPS
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Higher Child-Pugh score before TIPS
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Lower serum sodium levels
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: PPG reduction
Number of subjects: 341
Study: 35869891

Group type: EXPERIMENTAL
Intervention: Presence of Sleep-related Breathing Disorders (SRBDs)
Number of subjects: 58
Study: 35870093

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 833

Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 833

Group type: COMPARATOR
Intervention: Pneumonia
Number of subjects: 833

Group type: COMPARATOR
Intervention: Anemia
Number of subjects: 833
Study: 35870177

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 10954

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 10954
Study: 35870368

Group type: EXPERIMENTAL
Intervention: Modified prophylaxis regimen with alemtuzumab infusion (5 consecutive days for Course 1, 3 consecutive days for Course 2), including intravenous methylprednisolone 500mg and oral prednisone 50mg, along with oral H1 and H2 antihistaminics.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard prophylaxis regimen with alemtuzumab infusion at Bayshore centers.
Number of subjects: 57
Study: 35870472

Group type: EXPERIMENTAL
Intervention: ExtractEHR automated package
Number of subjects: 1077
Study: 35870702

Group type: EXPERIMENTAL
Intervention: JNJ-3989 100 to 400 mg Q4W
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: JNJ-3989 plus NA (with/without JNJ-6379)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: JNJ-3989 Q4W (200 mg) plus oral JNJ-6379 250 mg daily for 12 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 84
Study: 35870926

Group type: EXPERIMENTAL
Intervention: Grade 4 full-year mean daily school-day MVPA
Number of subjects: 4936

Group type: COMPARATOR
Intervention: Students attaining 30+ minutes of daily school-day MVPA
Number of subjects: 4936
Study: 35870979

Group type: EXPERIMENTAL
Intervention: Intelligent Physical Exercise Training (IPET), one hour/week individualized exercise during working hours for 12 weeks, with the first 8 weeks supervised and the last 4 weeks home-administered.
Number of subjects: 24
Study: 35871040

Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy (IVC) with gemcitabine
Number of subjects: 345

Group type: COMPARATOR
Intervention: Intravesical chemotherapy (IVC) with saline
Number of subjects: 345
Study: 35871069

Group type: EXPERIMENTAL
Intervention: Irradiated carotids
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control carotids
Number of subjects: 26
Study: 35871145

Group type: EXPERIMENTAL
Intervention: Preanestes@s web-based application and PreQuest questionnaire
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Final version of Preanestes@s and PreQuest
Number of subjects: 880
Study: 35871310

Group type: EXPERIMENTAL
Intervention: BNT162b2 booster vaccination
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (matched healthy controls)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Active treatment (rituximab, BTKi treatment)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Suboptimal responses post-second dose
Number of subjects: 193
Study: 35871677

Group type: EXPERIMENTAL
Intervention: Pregnant women at 26-28 weeks of gestation
Number of subjects: 2491

Group type: EXPERIMENTAL
Intervention: Offspring at birth
Number of subjects: 2491

Group type: EXPERIMENTAL
Intervention: Offspring at 6 years of age
Number of subjects: 2491

Group type: EXPERIMENTAL
Intervention: Non-pregnant women
Number of subjects: 2491

Group type: EXPERIMENTAL
Intervention: Maternal lipid profiles
Number of subjects: 2491
Study: 35871922

Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) screening tool for sarcopenia
Number of subjects: 118
Study: 35871930

Group type: EXPERIMENTAL
Intervention: RWR therapy (liraglutide, leucine-rich amino acid infusion, hypocaloric diet)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard 6-month bridging with IB (historic control)
Number of subjects: 26
Study: 35872072

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Enterography (MRE) based index (PICMI)
Number of subjects: 159
Study: 35872137

Group type: EXPERIMENTAL
Intervention: Left ventricular diastolic function parameters (e', E/e', LV mass index)
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Categorical classification of left ventricular diastolic dysfunction (LVDD)
Number of subjects: 2082
Study: 35872377

Group type: COMPARATOR
Intervention: Medium-dose BDP/FF/G
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose BDP/FF/G
Number of subjects: 0
Study: 35872509

Group type: EXPERIMENTAL
Intervention: Epigenetic gene alterations (EGA) identified through whole exome sequencing (WES) in patients with metastatic solid tumours.
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Presence of epigenetic gene alterations (EGA)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Co-occurrence of EGA with driver gene alteration
Number of subjects: 292
Study: 35872563

Group type: EXPERIMENTAL
Intervention: Children's Depression Scale
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Walter Reed Visual Assessment Scale
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cobb method (scoliosis severity)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Anterior trunk rotation
Number of subjects: 31
Study: 35872644

Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) VL testing using Cepheid Xpert
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) VL testing
Number of subjects: 541

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) VL testing
Number of subjects: 541
Study: 35872693

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic
Number of subjects: 31
Study: 35872777

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil or mycophenolic acid (MMF/MPA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No MMF/MPA
Number of subjects: 132
Study: 35872799

Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 62

Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 62
Study: 35873000

Group type: EXPERIMENTAL
Intervention: Tofacitinib (Tofa) 5 mg twice a day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tofacitinib (Tofa) at 200, 400, or 800 nM
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tofacitinib (Tofa)
Number of subjects: 9

Group type: COMPARATOR
Intervention: TNFα
Number of subjects: 9
Study: 35873264

Group type: EXPERIMENTAL
Intervention: Real cTBS and real SCRT
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham cTBS and real SCRT
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham SCRT
Number of subjects: 72

Group type: COMPARATOR
Intervention: No interventions (age- and gender-matched controls)
Number of subjects: 72
Study: 35873364

Group type: EXPERIMENTAL
Intervention: Tailored web-based EF intervention
Number of subjects: 0
Study: 35873420

Group type: EXPERIMENTAL
Intervention: Infant formula with 1.5 g/L HMOs (test group 1, TG1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant formula with 2.5 g/L HMOs (test group 2, TG2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard cow's milk-based infant formula (control group, CG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human milk-fed group (HMG)
Number of subjects: 0
Study: 35873652

Group type: EXPERIMENTAL
Intervention: Salvage radiotherapy (SRT) with 70 Gy in 35 fractions, adapted after 50 Gy, with sequential lymph node irradiation for non-responders.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PSMA-PET imaging at baseline and treatment planning consideration for non-responders after 50 Gy.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes regarding side effects.
Number of subjects: 100
Study: 35873764

Group type: EXPERIMENTAL
Intervention: Cumulative personalized intervention using EEG-based brain-computer interface, multi-channel functional electrical stimulation, and hand exoskeleton for upper-limb rehabilitation.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Addition of non-invasive brain stimulation (anodal transcranial direct current stimulation) to the initial approach in the second phase of the intervention.
Number of subjects: 30
Study: 35874156

Group type: EXPERIMENTAL
Intervention: Increasing Duration of rTMS treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing Intensity of rTMS treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing Duration and Intensity of rTMS treatment
Number of subjects: 0
Study: 35874466

Group type: EXPERIMENTAL
Intervention: Neutralizing anti-Tim-3 antibodies
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Neutralizing anti-PD-1 antibodies
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Soluble Tim-3 levels
Number of subjects: 98
Study: 35874558

Group type: EXPERIMENTAL
Intervention: Full ADBB scale
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Modified ADBB scale
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both scales
Number of subjects: 145
Study: 35874564

Group type: EXPERIMENTAL
Intervention: Norepinephrine at 0.2 μg/kg/min
Number of subjects: 14
Study: 35875477

Group type: EXPERIMENTAL
Intervention: Yoga-based program
Number of subjects: 256

Group type: COMPARATOR
Intervention: Structured exercise program (SEP)
Number of subjects: 256
Study: 35875816

Group type: EXPERIMENTAL
Intervention: Targeted drugs based on druggable ctDNA alterations identified by next-generation sequencing (NGS)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Physician-chosen treatment for patients without druggable ctDNA alterations
Number of subjects: 223
Study: 35875815

Group type: EXPERIMENTAL
Intervention: PCS severity score developed in sub-cohort Kiel-I based on 12 long-term symptom complexes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCS score replication and identification of clinically meaningful predictors in validation sub-cohorts (Würzburg/Berlin, Kiel-II).
Number of subjects: 0
Study: 35875853

Group type: EXPERIMENTAL
Intervention: PRECISE-DAPT score at baseline
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: PRECISE-DAPT score reassessed during follow-up
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: PRECISE-DAPT score at follow-up
Number of subjects: 480
Study: 35876084

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dental care adaptation for obese individuals
Number of subjects: 0
Study: 35876120

Group type: EXPERIMENTAL
Intervention: 6-month multicomponent training (MCT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual lifestyle (Control group)
Number of subjects: 102
Study: 35876145

Group type: EXPERIMENTAL
Intervention: Fixed meal times (8:00 am, 1:00 pm, 6:00 pm)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Everyday life conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fixed meal times
Number of subjects: 36
Study: 35876164

Group type: EXPERIMENTAL
Intervention: Neonatal NK cells from congenitally CMV infected newborns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 0
Study: 35876255

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35876391

Group type: EXPERIMENTAL
Intervention: NAC with increased Let-7a
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NAC with decreased miR-145
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NAC with reduced Let-7a
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NAC with reduced miR-145
Number of subjects: 120
Study: 35876408

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) measurement
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Target vessel failure (composite of cardiac death, target vessel myocardial infarction, or clinically driven target vessel revascularization)
Number of subjects: 1889
Study: 35876418

Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment
Number of subjects: 0
Study: 35876452

Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI)
Number of subjects: 20
Study: 35876473

Group type: EXPERIMENTAL
Intervention: External anal sphincter (EAS) muscle function assessment
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Puborectal muscle (PRM) function assessment
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Association between muscle function and number of PFS
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Absence of PFS
Number of subjects: 199
Study: 35876634

Group type: EXPERIMENTAL
Intervention: High-density surface electromyography (HD-sEMG)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 91

Group type: COMPARATOR
Intervention: Current methods for muscle evaluation (including DXA, handgrip strength, and physical performance)
Number of subjects: 91
Study: 35876637

Group type: EXPERIMENTAL
Intervention: Overall diet quality score (max score 30)
Number of subjects: 7736

Group type: EXPERIMENTAL
Intervention: Saturated fat score (max score 18)
Number of subjects: 7736

Group type: EXPERIMENTAL
Intervention: Diet quality scores by GBD region
Number of subjects: 7736

Group type: EXPERIMENTAL
Intervention: Atherosclerotic cardiovascular risk scores
Number of subjects: 7736
Study: 35876646

Group type: COMPARATOR
Intervention: No prior vascular disease
Number of subjects: 37198

Group type: EXPERIMENTAL
Intervention: Single-territory vascular disease
Number of subjects: 37198

Group type: EXPERIMENTAL
Intervention: Multisite artery disease
Number of subjects: 37198
Study: 35876660

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (blood glucose level <3.0 mmol/L)
Number of subjects: 94
Study: 35876678

Group type: EXPERIMENTAL
Intervention: Direct brainstem stimulation at 2 mA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Direct brainstem stimulation at 1 mA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall sensitivity and specificity for the association of stimulation intensity and DS-to-T
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative evaluation using modified Ranking Scale and motor function
Number of subjects: 30
Study: 35876699

Group type: EXPERIMENTAL
Intervention: High levels of CCL19 and CCL21
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: High levels of CCL21 at admission
Number of subjects: 414
Study: 35876706

Group type: EXPERIMENTAL
Intervention: mRNA-1273 by Moderna
Number of subjects: 0

Group type: COMPARATOR
Intervention: BNT162b2 by Pfizer-BioNTech
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preinfection with SARS-CoV-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly PWH and those with low CD4+ cell count
Number of subjects: 0
Study: 35876829

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents plus best medical practice (BMP)
Number of subjects: 1625

Group type: COMPARATOR
Intervention: BMP alone
Number of subjects: 1625

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents plus BMP
Number of subjects: 1625
Study: 35876960

Group type: EXPERIMENTAL
Intervention: 3D convolutional neural network (CNN) using functional MRI data
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Majority voting strategy with 3D CNN
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Voxel-wise visualization method based on convolutional filters
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Functional MRI traits analysis of misclassified patients
Number of subjects: 29
Study: 35876974

Group type: EXPERIMENTAL
Intervention: D-Pd (Daratumumab, Pomalidomide, Dexamethasone)
Number of subjects: 479

Group type: COMPARATOR
Intervention: D-Vd (Daratumumab, Bortezomib, Dexamethasone)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Vd (Bortezomib, Dexamethasone)
Number of subjects: 479
Study: 35877061

Group type: EXPERIMENTAL
Intervention: Collateral-core ratio (CCR)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Prediction model without CCR
Number of subjects: 129
Study: 35877070

Group type: EXPERIMENTAL
Intervention: ECV ≥ 30%
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Risk-stratification model based on LGE, LVEF ≤ 35%, and ECV ≥ 30%
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Comprehensive CMR evaluation
Number of subjects: 703
Study: 35877091

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 386
Study: 35877173

Group type: EXPERIMENTAL
Intervention: Omacor (omega-3 polyunsaturated fatty acids)
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Digital reporting of adherence
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Clinic-based enquiry
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Health-related quality of life data from digitally engaged patients
Number of subjects: 2167
Study: 35877269

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 298
Study: 35877687

Group type: EXPERIMENTAL
Intervention: Clinical criteria for stratifying risk of injuries to the abdomen and pelvis among adult blunt trauma patients.
Number of subjects: 6340

Group type: EXPERIMENTAL
Intervention: Decision instrument based on clinical criteria.
Number of subjects: 6340

Group type: EXPERIMENTAL
Intervention: Evaluation of the decision rule among a new cohort of patients in Phase 2.
Number of subjects: 6340
Study: 35877767

Group type: EXPERIMENTAL
Intervention: LPS stimulation of blood leukocytes
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of host response biomarkers
Number of subjects: 77
Study: 35877785

Group type: EXPERIMENTAL
Intervention: Telemedicine for preanesthesia consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35878076

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 24343

Group type: EXPERIMENTAL
Intervention: Nurses in high-risk settings
Number of subjects: 24343

Group type: EXPERIMENTAL
Intervention: Nurses in low-risk settings
Number of subjects: 24343

Group type: EXPERIMENTAL
Intervention: Black or Hispanic nurses
Number of subjects: 24343

Group type: COMPARATOR
Intervention: Nonnurse HCWs
Number of subjects: 24343
Study: 35878569

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation Program (PRP) for 4 weeks
Number of subjects: 80
Study: 35878640

Group type: EXPERIMENTAL
Intervention: Cochlear Osia 2 System
Number of subjects: 29
Study: 35878676

Group type: EXPERIMENTAL
Intervention: Antidepressant drugs (AD) treatment for 6 months
Number of subjects: 377
Study: 35878714

Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic body radiotherapy (SBRT) at 30-35 Gy/5 fractions to the prostate and seminal vesicles, and 25 Gy/5 fractions to the pelvic lymph nodes.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic body radiotherapy (SBRT) followed by radical prostatectomy (RP).
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Neoadjuvant SBRT followed by RP.
Number of subjects: 16
Study: 35878737

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35878742

Group type: EXPERIMENTAL
Intervention: Hepatic cGVHD diagnosed based on NIH Consensus Criteria (NCC)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Abnormal liver tests (ALT, AST, ALP, GGT)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Histologic features of GVHD
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Total cholesterol >220 mg/dL
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Cytokine profiles
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Decreased platelet count
Number of subjects: 302
Study: 35878932

Group type: EXPERIMENTAL
Intervention: Personalized 6-month walking exercise program at home
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: High adherence subgroup (>60% of prescribed sessions) to the walking exercise program
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Bayesian analysis of the exercise program
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses restricted to hospitalization risk
Number of subjects: 227